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Neurotrofiini aivoperäinen hermokasvutekijä (BDNF) osallistuu keskeisellä tavalla hermo-
so-lujen suojaamisen, erilaistumisen, ja muovautuvuuden säätelyyn. Monet kansantalou-
delli-sesti merkittävät hermosairaudet on liitetty BDNF proteiinin ilmentymisen ja/tai toimin-
nan häiriöihin.  
 
Professori Eero Castrénin tutkimusryhmä on aiemmin pystyttänyt BDNF proteiinin mittaa-
miseen käytettävän ELISA (enzyme-linked immunosorbent assay) menetelmän. Menetel-
mä pohjautuu keskeisesti hiiressä tuotettuihin monoklonaalisiin vasta-aineisiin. Tämän 
opin-näytetyön tavoitteina on ollut tunnistaa uusia vasta-ainepareja käytettäväksi mene-
telmässä sekä itse menetelmän validointi. Menetelmä optimoitiin sensitiivisyyden, selektii-
visyyden, detektiomenetelmän ja standardinsuoran suhteen. 
 
Tutkimuksissa löydettiin erittäin toimiva vasta-ainepari, ja niihin perustuva menetelmä se-
lektiivisesti tunnisti neurotrofiiniperheen kasvutekijöistä ainoastaan BDNF proteiinia. Myös 
menetelmän herkkyys parani: lopullinen detektioraja ~15,2 pg/µl. Työssä tutkittiin lisäksi 
värireaktioon eli kolorimetriseen mittaukseen perustuvaan standardimittauksen rinnalla 
mahdollisuutta käyttää kemiluminesenssiin perustuvaa mittausta. Kyseinen mittaustapa 
näytti lupaavalta mutta jatkotutkimuksia tarvitaan sen validoimiseksi analyyttiseksi mene-
telmäksi. Kaiken kaikkiaan opinnäytetyöltä vaadittavat tavoitteet saavutettiin selvästi. 
 
 
 
 
 
 
 
 
 
 
 
 
Avainsanat BDNF, ELISA, neurotrofiini 
Abstract 
 1 
Author 
Title 
 
Number of Pages 
Date 
Hanna-Kaisa Vikkula 
Optimization of BDNF ELISA 
 
25 pages + 2 appendices 
2 December 2013 
Degree Bachelor of Laboratory Services 
Degree Programme Laboratory Sciences 
  
Instructor(s) 
 
Tomi Rantamäki, PhD, Docent 
Juha E. A. Knuuttila, M. Sc, Lecturer 
Brain derived neurotrophic factor, BDNF, regulates the survival, differentiation and 
plasticity of neurons. Emerging evidence suggests that many highly prevalent and 
disabling nervous system disorders are associated with altered synthesis and functions of 
BDNF. 
 
Eero Castrén’s research group has previously set up an ELISA (enzyme linked 
immunosorbent assay) for the detection of BDNF. The aim of the thesis was to optimize 
the ELISA method for the detection of brain derived neurotrophic factor (BDNF) with a new 
antibody combination and validate the optimized method. The method was optimized for 
sensitivity, selectivity, detection methods and for the standard curve. 
 
A new antibody combination was found. The new combination was more sensitive than the 
previous combination. The new minimum detection limit was ~15 pg/µl. The antibody 
combination was also specific only to BDNF when tested with other molecules of the same 
neurotrophin family. The method was based on colorimetric detection.  
 
Furthermore, the potential utilization of chemiluminescence based detection method was 
tested. This detection method showed promising but further studies are needed to validate 
its use for analytical assay.   
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BDNF Brain-derived neurotropic factor 
ELISA Enzyme-linked immunosorbent assay 
NGF  Nerve growth factor 
TrkB Tropomyosin related kinase B 
p75(NTR) Low-affinity nerve growth factor receptor  
CNS Central nervous system 
PBS Phosphate buffered saline  
PBS-T Phosphate buffered saline with Tween-20 
BSA Bovine serum albumin  
HEPES 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid 
NP Lysis buffer 
PCR  Polymerase chain reaction 
DNA Deoxyribonucleic acid 
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LOD Limit of detection  
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Introduction 
Neurotrophin BDNF (brain-derived neurotrophic factor) regulates the survival, differen-
tiation and plasticity of neurons. Emerging evidence suggests that many highly preva-
lent and disabling nervous system disorders are associated with altered synthesis and 
functions of BDNF. For example reduced BDNF signalling is implicated with the patho-
physiology of Alzheimer´s disease and depression. Moreover, many clinically used 
drugs seem to act, at least in part, by increasing the synthesis and functions of BDNF 
in the brain. Therefore, methods that allow sensitive and specific quantification of 
BDNF in brain tissues and bodily fluids are important in clinical and experimental re-
search. Enzyme-linked immunosorbent assay (ELISA) is relatively straightforward and 
sensitive method for the detection of small quantities of proteins and other analytes 
including BDNF. 
Dr. Eero Castrén´s laboratory at the Neuroscience Center, University of Helsinki, have 
previously developed and used BDNF ELISA method to analyse BDNF protein levels in 
rodent brain tissues and rat and human blood(Karpova et al., 2010, Spulber et al., 
2010). The aim of this thesis was to further optimize this method and to set up and uti-
lize new antibody clones for the methodology. Such effort was required as the previous 
antibodies were running low.  
The study firstly introduces the theoretical background of neurotrophins, outlines the 
ELISA method and illustrates the antibody production of BDNF antibodies. Then the 
materials and methods were outlined. The results were illustrated after the materials 
and method. The results were then discussed and the validation plan was drafted. 
Lastly the conclusions of the study were discussed.  
1 Theorerical Background 
To appreciate the significance of the brain derived neurotrophic factor the history lead-
ing up to its discovery is vital. The discovery of the nerve growth factor lead way to the 
understanding of the role of neurotrophins in the mammalian nervous system. The neu-
rotrophin family bring on a cascade of changes in the mammalian brain which allow for 
the development and refinement of the brain.   
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Nerve growth factor or NGF was discovered by Rita Levi-Montalcini in 1956. Levi-
Montalcini’s discovery of NGF spurred the other discoveries of the different families of 
neurotrophins. Her research took place before, during, and after the Second World 
War.  
Born into a Jewish family in 1909, Rita Levi-Montalcini grew up in a well-off intellectual 
family. Levi-Montalcini was motivated to pursue a career in medicine though it was not 
common in the era for women to attend education which would interfere with martial 
and maternal obligations. Already during her schooling she began working in research 
under histologist Giuseppe Levi, staining nerve cells with the silver staining method 
developed by Camillo Golgi. The staining method proved to be the key method in her 
research success. In 1939, due to the anti-Semitic environment, Levi-Montalcini was 
forced to conduct her research undercover in her secret laboratory she built into her 
bedroom. She worked with chicken embryos to study the formation of limbs by viewing 
neuronal development. She noted that neurons still developed and differentiated 
though a developing limb had been removed. The neurons only started to degenerate 
after they had reached the stump of the amputation site. In 1942 Levi-Montalcini and 
her family fled from Turin and moved into a rural cottage where she continued her re-
search, though only for a short time as Mussolini was overthrown by German troops. 
Levi-Montalcini and her family then fled to Florence until the end of the war. (Zeliadt, 
2013) 
After the Second World War, Levi-Montalcini resumed working at the Turin University. 
In 1946, she received a letter from Victor Hamburger, the author of an article that had 
spurred Levi-Montalcini’s research to investigate the neurons involved with limb for-
mation in the chick embryos. She then moved to St. Louis to repeat and expand her 
findings with Dr. Hamburger in 1947. This move was to last for the next 30 years. Her 
research moved onto observing the behaviour of tumours implanted into chicken em-
bryos. In her observations she found that the nerve cells did not make direct contact 
with the tumour cells, so she hypothesised that the tumour secreted a growth promot-
ing factor for the neurons. To determine if the growth-promoting agent was a nucleic 
acid or protein, a solution of tumour cells and snake venom was used. Snake venom 
contains phosphodiesterase, an enzyme which degrades nucleic acids. The results of 
the experiment were opposite to what were expected as the snake venom enhanced 
the growth promoting effects of the tumours. Stanley Cohen, one of Levi-Montalcini’s 
colleagues, identified the protein that was later named as the NGF.  Levi-Montalcini 
and Cohen started searching for the growth factor in other tissues as the extraction of 
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the growth factor would have been too expensive and tedious from the snake venom. 
Cohen serendipitously found that male mouse salivary glands contained a tenfold con-
centration of the NGF which they were able to purify in large quantities (Zeliadt, 2013). 
Since the discovery of NGF the science of growth factors has become vital part in the 
study of brain and organism development. This thesis concentrates on the brain-
derived neurotrophic factor (BDNF). 
 
1.1 BDNF 
The following figure depicts the crystalline structure of the Neurotrophin family. It is vital 
to note the similar structures of the molecules. 
Figure 1. 
 The neurotrophin family. Picture edited from (Allen et al., 2013) with permission from Else-
vier  
BDNF belongs to the NGF family of neurotrophic factors (including also NT-3 and NT-
4/5) and shares about 50% amino acid identity with this neurotrophin family (Binder 
and Scharfman, 2004). BDNF was discovered by Yves-Alain Barde, David Edgar and 
Hans Thoenen in the beginning of the 1980´s (Barde et al., 1982). After its discovery, 
numerous studies have been completed in understanding its neurophysiology. Emerg-
ing evidence shows that BDNF critically regulates the development and survival of 
subpopulation of neurons in the peripheral nervous system(Huang and Reichardt, 
2001). In the developing and adult central nervous system (CNS), the important role of 
BDNF in regulating neuronal and synaptic plasticity, neurogenesis and neuronal differ-
entiation has been well characterized. Indeed, abnormal BDNF synthesis and functions 
has been associated with variety of nervous system disorders including neurodegener-
ative disorders, anxiety and depression. On the other hand, many clinically used drugs, 
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particularly antidepressant drugs, seem to act, at least in part, by promoting the ex-
pression of BDNF and its signalling in the brain (Castrén and Rantamäki, 2010). 
The Bdnf gene in humans is found on chromosome 11p, has eleven 5’ exons and one 
3’ exon that encode the mature BDNF protein (Pruunsild et al., 2007). BDNF is initially 
synthesized as an uncleaved precursor protein, pro-BDNF. Most importantly, pro-
BDNF has different binding characteristics and distinct biological activities in compari-
son with the mature BDNF protein (Teng et al., 2005). The mature-BDNF binds with 
high affinity to TrkB tyrosine kinase receptors. Upon BDNF binding TrkB receptors are 
dimerized and autophosphorylated, which further leads to activation of signalling cas-
cades that regulate neurotrophic and neuroplastic changes in the cell. However, the 
pro-BDNF preferentially binds p75 neurotrophin receptor or also known as low-affinity 
nerve growth factor receptor (p75NTR), a member of tumor necrosis factor family recep-
tors, and thereby produces opposite changes on neuronal function such as apoptosis. 
p75NTR is predominantly expressed during the early neuronal development. However, 
various pathological conditions, including epilepsy, axotomy and neurodegeneration, 
can induce p75NTR expression in the adult brain.  
The amino acid sequence for the rodent and human mature BDNF is identical. There-
fore produced mature BDNF protein is very similar in these species, and can be de-
tected by similar methods. There are some differences with the protein folding thus the 
pro-BDNF form can differ between the different species (Aid et al., 2007). 
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 Figure 2 depicts the crystalline structure of the Trk and p75 NTR reseptors.  
 
Figure 2.  The crystalline structure of Trk and p75NTR receptors, image edited from (Allen et al., 
2013) with permission from Elsevier  
1.1.1 BDNF antibody production 
Antibodies are commonly produced by injecting an antigen into a target animal and 
allowing the animal’s immune response to produce antibodies.  
The antibodies used in the present study were monoclonal. The major advantage of 
monoclonal antibodies is that they target only one specific type of antigen. The BNDF 
antibodies used in the present study were produced by immunizing mice with chick, 
fish and mammalian BNDF (Kolbeck et al., 1999). Briefly, the mice were injected intra-
peritoneally with 70µg of fish BNDF in phosphate buffered saline (PBS), which were 
followed with three boosts of human BNDF 100µg each and four additional boosts with 
fish BDNF 70µg each. Three days before fusion, one mouse received three intrave-
nous injections of human BNDF in PBS 100 µg each. Next, the animal´s spleen cells 
were fused with non-secreting mouse myeloma cells. The positive hybridomans were 
cloned using a cell sorter. The positive hybridoma clones were selected in an immuno-
assay with immobilized neurotrophins.  These monoclonal antibodies have been shown 
to preferentially and specifically detect BDNF protein (Kolbeck et al., 1999).  
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1.2 Enzyme-linked Immunosorbent Assay as Analytical Method 
The ELISA method was invented by Eva Engvall and Peter Perlmaun in 1970. The first 
assay used cellulose as a particulate immunosorbent, but quickly was switched to plas-
tic due to the tedious phases of centrifugations. The application of the antibodies to the 
plastic resulted in a simple, robust, inexpensive, and efficient test. The test was initially 
tested in primitive conditions in East Africa. After the primary launch of the method, the 
applications of the method have been cited in numerous publications. Engvall and 
Perlmaun received the analytical biochemistry prize from the German Society for Clini-
cal Chemistry and the Smith Kline Bio-Science Laboratories award from the Clinical 
Ligand Assay Society. Engvall never patented the method. (Engvall and Perlmann, 
1971) 
Immunoassays are used as analytical methods to detect analytes with antibodies. En-
zyme immunoassays use enzymes attached to one of the reactants in an immunoas-
say to allow quantification. The quantification of analytes is done through the develop-
ment of colour or luminescence in addition to an enzyme specific substrate or chromo-
gen. 
Most commonly used ELISA method is the so called sandwich ELISA. The basic prin-
ciple of the method is as follows: an antibody is attached to the bottom of an ELISA 
plate. Generally a material is used on the bottom of an ELISA plate that allows for the 
antibodies to attach easily, an example of a specific ELISA plate material is Maxisorb 
from Thermo Scientific. Next the target protein (or a biological sample containing the 
analyte of interest) is added which then attaches to the antibody. The secondary anti-
body which has been labelled with an enzyme attaches itself to the target protein, and 
lastly an enzyme specific substrate is added which produces a detectable reaction. If 
the reaction is colorimetric, the reaction can be measured by eye or a spectrometer. 
For quantification a standard curve is analysed along with the analytes to solve the 
concentration of the analyte.   
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Figure 3.  Sandwich ELISA from (Leng et al., 2008) with permission from Oxford journals 
 
The advantages of sandwich ELISA are its high specificity, suitable for complex sam-
ples, flexibility and sensitivity. The high specificity comes from the two antibodies that 
are used thus the antigen is captured with a higher change of it being the correct ana-
lyte than in other methods. The method’s suitability for complex samples is possible 
due to the fact that the samples do not need any purification prior to the analysis. The 
flexibility of the analysis is achieved due to the many possible detection methods.  
The main disadvantages of the ELISA method are the manual labour phases, the mar-
gin for error, and the time taken for the analysis to be complete. The method often in-
volves pipetting samples individually into wells which requires quite large amounts of 
effort if  a bigger batch of samples needs to be analysed. The margin of error increases 
as the amount of phases of the method increase. The possibility of human error in-
creases every phase that there is human interference. The reliability of the materials 
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used also affects the error margin of the method. The accuracy should be followed with 
quality control. When the method is conducted correctly, the ELISA method is a valua-
ble and affordable method in the laboratory.  
2 Materials 
The samples, buffers and  the antibodies used in the present study are listed in detail 
below.Samples:  
The samples in this experiment were chosen to depict the applications of the method 
and to determine the best combination of antibodies. The applications of the method 
include clinical studies of BDNF levels in the human blood and research projects using 
animal tissues for BDNF analysis. The standards were the same as in the previous 
method which would depict how well the new antibody combination would perform. 
Reference antibodies were used in parallel with new, tested, ones. 
The following samples were chosen: 
 Serum  
(a) Human serum collected from six individuals and pooled together, 
anonymous sampling 
(b) Blood extracted from adult rats. Extracted straight from heart with sy-
ringe 
(c) Blood extracted from adult mice. Extracted with the same method as 
the rat samples 
 Brain tissue  
(a) Mouse brain lysates from postnatal day 1-3 old wild type, BDNF+/- 
and BDNF-/- mouse pups. Whole brain collected and frozen in -80°C 
until brain was lysed.  
 Standard recombinant human mature BDNF 
(a) 10 µg/ml stock BDNF diluted to standard concentration for standard 
curve  
Reagents and materials:  
The reagents and materials used were the same as the original method described in 
Karpova et al (2010). The reagents include the antibodies used in the experiments as 
well as the buffers needed for the ELISA protocol: 
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Buffers: 
 Coating buffer  
(a) Carbonate buffer: 50 mM NaHCO3 to which ~210 ml of 50 mM 
Na2CO3 added until pH 9.7 is reached  
 Blocking buffer  
(a) Hanks buffer with 2% BSA and 0.1% Triton X-100  
 Washing buffer 
(a) PBS-T (1:10 dilution of 10x PBS in MilliQ water with added 0.1% 
Tween  
 Secondary antibody dilution solution 
(a) Hanks buffer with additional 6.66% bovine serum albumin (BSA) and 
0.66% Triton X-100 
 Hanks Buffer (pH 7.4)  
(a) 125 mM NaCl 
(b) 5 mM KCl 
(c) 1,2 mM NaH2PO4 
(d) 1 mM CaCl2 
(e) 1,2 mM MgCl2 
(f) 1 µM ZnCl2 
(g) 10 mM Glucose  
(h) 25 mM HEPES 
(i) 0,25 % BSA  
(j) NaOH for pH adjusting if needed  
The antibodies were received in 2005 and stored at -80°C before testing. The antibod-
ies were labelled by corresponding letters to make the identification easier.  
Codes and concentrations:  
Primary antibodies:  
Ab1(A) 50 µl aliquots  1,618 µg/ml  
Ab1(B) 20 µl aliquots 3,60 µg/ml 
Ab1(C) 15 µl aliquots 5,78 µg/ml   
Ab1 reference antibody  
Secondary antibodies:  
Ab9(D) 3,92 µg/ml 
Ab9(E) 16,70 µg/ml 
Ab9 reference antibody  
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Antibodies Ab1(A), Ab1(B), Ab1(C), Ab9(D), Ab9(E),are hybridoma clones of the reference anti-
bodies thus are labeled with corresponding letters. 
The reference antibody combination was used as a control to compare the new combi-
nations with standard combination. 
Materials:  
 ELISA plate, Maxi Sorp Nunc Immunoplate (Thermo scientific)  
 Multi-channel pipette (Biohit eLine pro)  
 Plate mixer (Thermo scientific Mini mix)  
 Plate shaker (Labsystems Well Mix)  
 Plate washer (Thermo scientific Well Wash AC) 
 Cold room 
 Perkin Elmer Victor3 1420 Multilabel Counter 
The bufferes used in the study were prepared ahead of time so that there was 
enough buffers to last through the whole study so that the results could be 
compared. The ELISA plates were also kept conastant as they were found to 
be the same lot. The plate shakers and the washer were the same throughout 
the study.  
3 Method 
The following chapter depticts the flow of the method including the sample collection 
and the basic BDNF ELISA protocol. 
Sample Collection 
The samples needed for the experiments were from live specimens, thus the prepara-
tion required separate protocols which will be described below. Samples were collected 
from mice, rats and humans. The human blood samples were collected from volunteers 
and samples were kept anonymous. The blood samples were taken by an experienced 
technician with appropriate training and experience for the blood collecting procedure. 
The animal samples were taken from animals that were under the animal license 
ESAVI-2010-09002/Ym-23. 
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3.1.1 Rodent Brain Tissue Collection and Genotyping 
Mouse brain tissue was collected from wild-type, BDNF-/+ and BDNF-/- mice. BDNF-/- 
mice show abnormal development and typically die before postnatal week two (Ernfors 
et al., 1992). Therefore, the brain tissue samples were extracted from postnatal day 1-3 
old mouse pups. Briefly, after sacrifice the animal was decapitated. The skin above the 
skull was cut from the back of the head along the mid line towards the nose. With the 
skull exposed the skull was cut in a similar fashion as the skin, cut along the midline 
the scissors moving in an upwards movement as not to destroy the soft brain tissue. 
The skull was removed with tweezers by bending the skull halves towards the outside. 
The brain was then exposed and with tweezers closed the brain is scooped out and 
deposited into a clean eppendorph tube and frozen with dry ice and after stored in a -
80°C freezer until further processing.  
Next the brains were lysed in NP lysis buffer using glass-Teflon to allow for the BDNF 
extraction. The buffer consists of Nodinet detergent which breaks down cell mem-
branes and solubilizes BDNF. After the brain is completely lysed the solution is centri-
fuged at 16 000 g in 4°C for 10 minutes. The resulting supernatant is collected into a 
clean eppendorph tube and frozen for the analysis. (Karpova et al., 2010, Karpova, 
2013)  
The animals that were used for the samples needed to be genotyped so that the sam-
ples could be identified either as knock-out, heterozygous, or wild-type tissue. The 
genotyping samples were collected at the same time as the brain tissue samples. A tail 
piece of the specimen was collected and transferred into a clean eppendorph tube. The 
tailpieces were digested with a commercial mouse genotyping kit (KAPA mouse geno-
typing kit). PCR was performed for the digested DNA samples. After the PCR the re-
sulting DNA fragments were separated with gel electrophoresis. The gels were treated 
with ethidium bromide so that the DNA segments would be clearly visible under ultra 
violet light. After the samples had run into the gel for a time period of ~20 minutes, the 
gel was imaged with UV light. The results were interpreted from the image. The DNA 
fragments are sized as following: wild type fragment ~275 base pairs, heterozygous 
fragments ~275 and ~340 base pairs, knock out fragment ~340 base pairs. The follow-
ing image depicts the fragments by which the genotyping result is decided.  
  46 
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Figure 4 depicts the genotyping results of BDNF-null mice brain tissue:  
 
Figure 4.  BDNF Genotyping image. From left Heterozygous control and wild type control and 
50 bp marker. Samples 46-59. 55 and 56 are knock-out mice  
 
The genotyping ensures that the samples are the correct genotype so that they can be 
used as controls for the analysis. The method requires testing so the genoltyped brain 
samples are used to test if the method can detect different amounts of BDNF from ro-
dent brain tissue.  
3.1.2 Acidic Treatment of Brain Tissues 
After the brain tissues were lysed the samples had to be acid treated to free the possi-
ble BDNF from the binding proteins usually associated with BDNF. The binding pro-
teins generally inhibit the immunological recognition of the BDNF thus resulting in an 
unreliable amount of BDNF in the sample (Okragly and Haak-Frendscho, 1997). Brief-
ly, 20µl of sample lysate was diluted into 175 µl of Hanks buffer which was acidified 
with 6 µl of 1 M hydrochloric acid (HCl) and allowed to incubate at room temperature 
for 15 minutes. The pH of the sample was measured with broad range (1-14 pH) pH 
paper. The pH of the solution had to drop to pH 3 during incubation. After the incuba-
tion period, 6 µl of 1 M sodium hydroxide (NaOH) was added to neutralize the solution. 
The pH of the solution was measured again to detect the neutralization of the solution. 
The pH of the solution after neutralization had to be pH 7 so that the ELISA analysis 
could be conducted (Okragly and Haak-Frendscho, 1997).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
3.1.3 Blood Collection from Rats and Mice 
Blood samples were collected from adult rats and mice. Briefly, the animal was stunned 
with CO2 and the neck was dislocated.  
TG WT KO KO 
55 56 59 
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The animal was then turned so that it was lying on its back and a needle was inserted 
gently to the right sternum. The needle was inserted approximately one centimetre into 
the thorax and then the sample of blood was extracted straight from the heart. From a 
rat approximately 10 ml of blood was collected and from a single mouse approximately 
3 ml of blood was collected. The samples were allowed to incubate at room tempera-
ture for approximately one hour so that the blood coagulated. After the hour the sam-
ples were spun down at 3500 rpm for 15 minutes. After the samples were spun down 
the supernatant was decanted into clean tubes and frozen until the serum samples 
were needed for analysis.  
3.1.4 Human Blood Sample Extraction 
Six adult voluntary individuals were chosen (three female and three male) and blood 
was collected intravenously with a vacuum tube. The samples were collected in the 
same fashion as in clinical trial of BDNF. Generally the blood samples are collected 
without vacuum as not to activate the BDNF found in blood platelets. So that the results 
of the analysis could be compared to the clinical trial method the samples were collect-
ed with a vacuum tube. Samples were labelled with numbers randomly so that the an-
onymity was preserved. Samples were allowed to stand for an hour at room tempera-
ture and then centrifuged at 3500 rpm for 15 minutes. The serum was removed into 
clean tubes, pooled and frozen until the samples were to be used in the analysis. Sam-
ples were collected by Outi Nikkilä, Research Technician.    
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3.2 Basic ELISA Protocol 
The following flow chart in Figure X  illustrates the progression of the ELISA protocol: 
Figure 5. Flow chart of the ELISA protocol 
To familiarize the method, the ELISA was done essentially as described in Karpova et 
al (2010) using the reference antibodies. Briefly, the preparation of the 96-well plate 
was the first step of the method. The preferred material of the 96-well plate was Max-
isorb® (Thermo Scientific). The primary antibody was diluted to suitable concentrations 
(1:4000).  Pipetted 200 µl/well of antibody dilution and sealed the plate. Plate was in-
cubated overnight at 4°C in the cold room on a shaker at level 4 of the shaker (approx-
imately 400 rpm) to ensure proper attachment of the antibody to the bottom of the well. 
The next day the coating buffer was removed and the plate was tapped onto a paper 
towel to remove excess coating buffer. Next the plate was blocked with 300 µl per well 
of blocking buffer for two hours at room temperature on a shaker 400 rpm.  
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Samples were prepared with an acid treatment if needed. For human, rat, and mouse 
serum or plasma acid treatment was not required. Samples were diluted 1:25 into 
Hanks buffer. Also the standard curve dilutions were prepared (1000, 500, 250, 125, 
62.5, 31.2 pg/µl) 170 µl of the sample dilutions was added to each corresponding well. 
30 µl of peroxidise conjugated BDNF antibody dilution is added to each well. The plate 
was left to incubate over night at 4°C on a shaker at 400 rpm. Figure 5 depicts a chart 
used for the analysis. 
 
Figure 6. Pipetting chart for BDNF ELISA 
On the final day the plates were washed four times with 300 µl/well of PBS-T. After 
washing, 200 µl of POD substrate was added to each well and allowed to incubate for 
20 min in room temperature in a dark place. The reaction was then stopped with 50 µl 
of sulphuric acid (1N H2SO4). The intensity of the colour was measured with the spec-
trometer Victor at the wave length 490 nm (Karpova et al., 2010).  
3.3 Antibody Combinations 
The new possible antibody pairs were tested separately so that the best pair could be 
determined.  
Firstly the protein concentration of antibodies measured with spectrometry at wave-
length A280 nm (Biorad). After protein concentration analysis proper dilutions of anti-
bodies were made so that they were equal to the concentration of the previous anti-
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body combination (Ab1 and Ab9). The concentrations of the antibodies were also 
changed to determine the best combination. The concentrations of the antibodies were 
increased three fold from the previous concentration and also decreased three fold 
from the ‘old’ concentration.  
3.4 Detection Methods 
The original detection method was a colorimetric detection, the reagent produced a 
colored reaction when exposed to the POD labelled secondary antibody. The POD 
reagent used for the method was a chromogenic substrate for the peroxidase-mediated 
colour development in ELISA assays. The POD Blue substrate turned a dark blue col-
our when in contact with the POD conjugated antibody and after the stop reaction liquid 
was added the colour changes from the blue to a bright yellow hue. The absorbance 
was read at 490 nm on a spectrometer (Roche, 2007). The more antibodies attached to 
the plate the higher the signal from the color forming reagent. The overdevelopment of 
the color was a concern with the method as the substrate began to precipitate as the 
stop reaction was added if the plate had been incubated for an unsuitably long time.  
Also a chemiluminescence was tested to improve the sensitivity of the method and 
ease the last steps of the analysis. Chemiluminescence is based on the signal gener-
ated in enzyme-catalysed light emitting reactions which is similar to the signal generat-
ed during radioactive decay. The horseradish peroxidase (POD) in the presence of 
hydrogen peroxide (H2O2) catalyses the oxidation of diacylhydrazides like luminol. A 
reaction product in an excited state is formed, which then decays to the ground state by 
emitting light (Roche, 2010). The light emitted can be measured with a chemilumines-
cence reader. The chemiluminescence reagent does not require a stop reaction after 
the incubation period so one phase of the analysis could be left out, lessening the hu-
man error aspect as the mixing phase of the stop reaction can be conducted in many 
ways differing from person to person. The chemiluminescence detection method re-
quires an opaque white plate so that the signal can be detected.  
Figure 7 depicts the reaction that produces the light signal in the chemiluminesence 
method: 
13 
 
   
Figure 7. Enzyme-induced generation of chemiluminescence and detection by photomultiplier. 
(Roche, 2010) 
3.5 Data Analysis 
The following variables were analysed in the basic protocol:  
 Sensitivity – How well the analysis determines the presence of different 
BNDF molecules.  
 Selectivity – Does the method detect other neurotrophins. Origin of the 
molecule can be from mice, humans or rats.  
 Standard curve – The standards form the standard curve from which the 
quantity of BDNF can be calculated, these calculations include the dilu-
tion factor of the samples.   
The variables that are analysed allow for the conclustion to be made which of the anti-
body combinations are the most suitable for the sample range that are to be analyzed 
after the optimization is completed for the method.  
4 Results 
The main findings of the experiments are outlined per experiment in the following sec-
tions: The following flow chat illustrates the procession of the whole thesis experiments  
Figure 8 
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Figure 8. Flow chart of the progression of the method 
Experiment 1: Antibody combinations 
All the primary and secondary antibodies were arranged into combinations so that all 
possible combinations were tested. In total six combinations of primary and secondary 
antibodies were tested. The antibody concentrations were also tested so that the con-
centrations of the antibodies were the same as the old antibody combination, three fold 
less, and three fold more than the original concentrations. Figure 9 illustrates the anti-
body combinations that would be tested in the experiments 
15 
 
 
Figure 9. : The Antibody combination detection of BDNF standard. 
 The antibody combinations that were excluded after the first combinations were tested 
were: Ab1(A) x Ab9(D), Ab1(A) x Ab9(E), Ab1(B) x Ab9(E), Ab1(C) x Ab9(E). The antibody combi-
nations that were the most linear were chosen for further thesting The combinations 
chosen as promising combinations for further testes were Ab1(B) x Ab9(D) and Ab1(C) x 
Ab9(D). The first experiment was to test the amount of primary antibody concentrations. 
The secondary antibody was kept constant, while the primary antibody concentrations 
were changed. Figure 4 illustrates the antibody combinations that showed interesting 
results that were to be tested further:  
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Figure 10. Antibody Ab1(B) x Ab9(D) and Ab1(C) x Ab9(D) combinations. The primary antibody 
concentration was changed with each combination. The volume of primary antibody pipet-
ted into the wells was as following: Ab1(B) 3,8 µl and 11,5 µl and for Ab1(C) 0,78 µl, 2,36 µl 
and 7,10 µl 
The standard dilutions were limited up to 1000 pg/µl due to the nature at which the 
samples began to persipitate as the concentration of the sample went above 1000 
pg/µl. The persipitaton in the color reaction caused the absorbance to taper significant-
ly thus causing issues with the linearity of the experiments. The future tests were com-
pleted with the standard curve dilutions ranging from 31,2 pg/µl to 1000 pg/µl. 
The antibodies were diluted to the same concentration as the old antibodies. The pipet-
ted amounts of antibody dilutions took into account the old antibody concentration and 
from that the three fold raise or decline of concentration. The Ab1(B) amounts of anti-
body that were to be tested further were 3,8 µl, 11,5 µl. The threefold increase of the 
concentration was not taken into account as the linearity was unacceptable to be used 
as a combination to be tested further. A possible error in the method for the combina-
tion occurred. For Ab1(C) the amounts of antibody that were to be tested were: 2,3 µl, 
7,1 µl and 21,3 µl.  
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After the first test of the first experiment, the selected combinations were tested with 
different concentrations of secondary antibody. The amount of antibody was changed 
in the same method as in the first test of the experiment 1. The secondary antibody 
concentration was kept at the same concentration as the reference antibody, increased 
by three fold decreased by three fold. The amount of secondary antibody pipetted onto 
the plates was as following: 9 µl, 3 µl, and 1 µl. 
Figure 11depicts the standard curve for the antibody combinations Ab1(B) 11.5 µl and 
Ab9(D) 1 µl, 3 µl and 9 µl, where as Figure 12depicts the antibody combination chosen 
for futher thesting. :  
  
Figure 11. Antibody combination Ab1(B)  and Ab9(D) 
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Figure 12. Antibody combination Ab1(B) x Ab9(D)  The volumes piptetted 11,5 µl Ab1(B) and 3 µl 
for Ab9(D). The combination gave the most linear curve thus being the most promising anti-
body combination.    
The most promising antibody combination was found to be Ab1(B) 11.5 µl, Ab9(D) 3 µl. 
The combination was used for further testing.   
Experiment 2: Methods of Detection 
The antibody combination Ab1(B) x Ab9(D) was chosen to determine the sensitivity of the 
method. The standard curve concentrations were diluted up to a known 7.8 pg/µl and 
the maximum was 1000 pg/µl. The analysis was able to detect a signal from the con-
centration 15.6 pg/µl upwards until 1000 pg/µl with the colorimetric method. The ab-
sorbances were above the limit of detection, the absorbance values were ranging from 
0.032 to 1,039. The analysis gave a signal for the concentration 7.8 pg/µl as well but 
the signal was very weak and could not be included as a detectable concentration. Two 
methods of detection were used for the analysis, chemiluminensence and colorimetric 
reagents.  
Figures 13 and 14 illustrate the signal intensity of the concentrations:  
Calorimetric results: 
The graph illustrates the absorbance of the BDNF standards after background subtrac-
tion. The absorbances below 15,6 pg/µl are below the detectable level of the analysis.  
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Figure 13.  Standard curve of the colorimetric detection method for the antibody combina-
tion Ab1(B) 11,5µl x Ab9(D) 3µl 
Chemiluminecense results:  
 
Figure 14.  Standard curve of chemiluminescense detection method for the antibody combi-
nation Ab1(B) 11,5µl x Ab9(D) 3µl  
The chemiluminescence method gave a clear signal for 7,8 pg/µl of BDNF after back-
ground subtraction, which suggests that the chemluminescence method would have a 
lower detection limit. The method though required more optimisation. The method of 
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detection could be changed to favour the chemiluminescent method due to its higher 
sensitivity.  
Experiment 3: Sensitivity and Selectivity 
As the antibody combination was established and the limit of detection detected, the 
next step was to determine the sensitivity and selectivity of the combination. The selec-
tivity was measured by how well the antibody combination recognized BNDF from dif-
ferent species including human, rat, and mouse serum samples and whether or not the 
antibody combination recognised other neurotrophins from the same family.  
Figure 9 illustrates the ability of the antibody combination to detect the amounts of 
BDNF from a mouse strain of Knock out, Heterozygous, and wild type animals. The 
graph illustrates t the results of the wild type expressing the most BDNF while the het-
erozygous expressing less and the knock out expressing an undetectable quantity of 
BDNF (Barde et al., 1982). 
 
 
Figure 15. BDNF concentration detected from Bdnf wild type (wt), heterozygous (het) and 
knock-out (ko)  tissues. Knock-out tissue samples were not detected (ND). Samples 
concentration calculated with a standard curve: y = 0,0007x + 0,0004. Samples had a 
confidence interval of 95%, for Wild type tissue 53,34, and for Heterozygous 36,35.    
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The figure 15 depicts the different amounts of BDNF detected from BDNF-null brain 
tissue lysates.The antibody combination produced a signal for the human, rat and 
mouse plasma and human and rat plasma samples are shown in Table 1.  
 
  
Abs pg/µl 
Human  Serum 0,743 642,2 
Plasma 0,119 18,2 
Rat Serum 0,121 20,2 
Plasma 0,137 36,2 
Table 1.  Human and Rat blood samples. Concentration calculated from a standard curve 
y = 0,0062x + 0,0188 with known concentrations ranging from 31,2 to 1000 pg/µl.  
The absorbances of the plasma and serum samples was above the detection limit and 
gave probable concentrations for the samples. 
. The following figure 16 depicts the detection of the other neurotrophins of the same 
family along side BDNF. 
 
 
Figure 16. Other neurotrophin detection from the same family of neurotrophins as BDNF 
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The antibody combination was not able to detect the other neurotrophins that were 
tested. NGF and NG-4/5 were not detected though they are from the same family as 
BDNF and were at a high concentration of 1000 pg/µl. The absorbances were under 
the detection limit thus neither of the neurotrophins was detected by the antibody com-
bination The results clearly depict the thought process through which the antibody 
combination was chosen and deemed to be reliable for the new method. 
5 Discussion  
In this study it was observed that a new antibody combination was found and was set 
up so that the method could be used in the laboratory to quantify the amount of BDNF 
in tissue, blood and cell culture samples. The antibody combination was more sensitive 
than the combination that had been previously been used. Validation would be needed 
in determining how reliable the method would be in the long run. A suggestion for this 
would be an inner control of the pooled serum samples.  
5.1 Samples 
The data points that the changing the antibody concentrations improved the sensitivity 
and selectivity of the method. The concentration changes were as following, keeping 
the secondary antibody concentration constant to our reference secondary antibody 
and keeping the concentration of the primary antibody constant to our referece primary 
antibody. Due to the antibody concentration differation between the reference antibod-
ies and the referene antiboduies, Ab1(B) 11,5µl is at the same concentration as Ab1,  con-
centration. The observed increase in sensitivity and selectivity was found with the anti-
body combination Ab1(B)11,5µl and Ab9(D) 3 µl. The amount of antibody pipetted into the 
buffers would be changed to 11.5 µl of the Ab1(B) into 26 µl of carbonate buffer and 3 µl 
of Ab9(D) into 3.8 µl of coating buffer.  
5.2 Sensitivity  
Facing the issue with the method of not being able to detect BDNF concentrations un-
der 31,2 pg/µl, it was tried to increase the sensitivity by changing the antibody combi-
nations to different clones from the said reference antibodies (Ab1 and Ab9). The data 
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points to the limit of detection being 15.8 pg/ml for the POD labelled antibodies and for 
the chemiluminescent reagent the results are inconclusive and require optimization. 
The sensitivity of the standard protocol is 31,25 pg/ml so the new antibody combination 
improves the sensitivity significantly.  
The method still needs to be optimized and requires validation in determining how well 
the limit of detection will stay stable. The results suggest that there is slight differation 
between plates which could limit the stability of the limit of detection.  
5.3 Selectivity  
The data points that the new antibody combination does not detect other neurotrophins 
of the same family, such as NGF and NT-4.  NT-3 was not analyzed so we are able to 
conclude that with almost complete certainty that the antibody combination does not 
detect any other neurotrophins other than BDNF. The antibodies also did not detect 
BNDF from bdnf-/- knock-out mice, but did detect intermediate levels in heterozygous 
animals and the most BDNF in wild type animals. The antibody combination detected 
BDNF in human and rat blood samples, thus suggesting that the method would be 
suitable for both human and rodent BDNF analysis.  
5.4 Validation Plan 
The method is set up so that the method has been optimized for the colorimetric meth-
od. The method though was not validated. The application of this method does not 
generally need comparable results as the results are being used for research purposes 
and not for diagnostics.  
The method could be validated as a future project to determine the reliability of the 
method. A good method of determining how well the method behaves on the long run 
is an inner standard. An inner standard in this method would be a sample that is pooled 
and has always the same so the concentrations of BDNF. The sample should have 
very little variation so that the variation between sample concentrations could be fol-
lowed to illustrate how the method stays stable or unstable. The concentrations of the 
inner standard could be followed for a long period of time to determine the standard 
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deviation and error margin of the method. The inner standard that was chosen for the 
method was a pooled serum sample of human blood from six individuals. The addition 
of the inner standard could possibly determine how well the method behaves on the 
long run.  
After the standard deviation and error margins are determined the analysis could be 
tracked on how reliable it is by using a simple graphing program that would illustrate 
how well the analysis stays within the acceptable error margins. In the graph the error 
margins would include a ‘warning’ phase where the results should be scrutinized but no 
action would be taken to correct the result. The warning phase would be the average ± 
two standard deviations. The action phase would also be included that would mean if a 
result would go into the phase; something would have to be done. The action phase 
would be the average of the results ± 3 standard deviations.   
Figure 17 illustrates the type of graphing method that could be used to determine the 
reliability of the ELISA method:  
 
Figure 17. Picture depicting an X-chart. Image edited from (Jestoi, 2012) (Labels translated 
into english from finnish) 
The BDNF ELISA method is known to be slightly unstable and the variation with results 
can vary depending on many factors. The introduction of a method of following the re-
sults could give a clear indication on the reliability of the method on a long run.  
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6 Conclusion 
The aim of the thesis was achieved in determining the new antibody combination for 
the BDNF ELISA method. The antibody combination that was chosen was Ab1(B) and 
Ab9(D). These new clones had a slightly better sensitivity than the previous combination 
but the sensitivity of the literature was not achieved. Due to the nature of the cloning 
process there can be small changes in the detection sensitivity.  
The method was specific to BDNF which was a key factor in its reliability. The data 
shows that the antibodies do detect BDNF molecules while they do not detect other 
neurotrophins of the same family. The knowledge that the method is specific to the 
detection of BDNF is key in the reliability of the method.  
The detection methods are a field in which there are other possible methods to improve 
sensitivity. The colorimetric method has been used in the past with success but it is not 
very sensitive and needs an extra step to end the colour forming reaction. The extra 
step of the detection process can cause unreliable data. The chemiluminescence 
method showed promise in improving the sensitivity of the method. The detection did 
not need a stop reaction which would take out the last step of the protocol which could 
reduce the probable error of the method. The luminescence stays constant for an hour 
after the reagents are added which provided a more stress-free detection.  Due to time 
restrictions, the chemiluminescence detection method was not optimized but could be a 
project that could be done as another project.  
 A validation plan was drafted for the improved method with inner standards of human 
serum samples so that the reliability and transparency of the method could have fol-
lowed. The validation plan could improve the criticism of the reliability of the method.  
The improved BDNF ELISA method has been used regularly after the optimization. The 
inner standards have been used to track the reliability of the method. The method has 
shown to be reliable for the detection of BDNF. The aims were achieved for the thesis.   
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BDNF Protocol BDNF ELISA 
 
By: Tomi Rantamäki (tomi.rantamaki@helsinki.fi, +358-41–5020978),  
Hanna Vikkula (hanna-kaisa.vikkula@helsinki.fi 
Date:  2.9.2013 
Description: ELISA-based method for the measurement of BDNF from mouse/rat brain and serum. 
Reliable sensitivity:  ~25-30 pg/ml (Abs after background subtraction >0.05) 
Important:  This protocol is based on Roche’s antibodies. If scientific data obtained by this method are 
considered for publication, the permission should be obtained from Roche.  
 
I. Preparation of the 96-well plate (Maxisorb, Nunc) 
 Primary BDNF antibody Ab#1_B (stored at -80°C) in 26 ml Carbonate buffer (1:4000,  
(e.g. 11,5 μl in 26ml; 200 μl/well). 
 Seal the plate and incubate overnight at +4ºC 
I.Blocking 
 add 300 μl/well of blocking buffer  
 2 hours at room temperature 
II.Sample preparations 
 Acidic treatment (“epitope release”) in regular 96-well plate 
(- optimal acidic treatment conditions should be done for the selected samples) 
- For NP++ lysed brain samples (conc. ~ 3-10 μg/μl) the following conditions can be used 
 Visual cortex: 30 μl of sample + 165 μl of Hanks + 6 μl 1M HCl  15 min  6 μl 1M NaOH 
 Prefrontal cortex: 15 μl of sample + 180 μl of Hanks + 6 μl 1M HCl  15 min  6 μl 1M NaOH 
 Hippocampus: 15 μl of sample + 180 μl of Hanks + 6 μl 1M HCl  15 min  6 μl 1M NaOH 
 Amygdala: 15 μl of sample + 180 μl of Hanks + 6 μl 1M HCl  15 min  6 μl 1M NaOH 
 Caudate putamen: 20 μl of sample + 175 μl of Hanks + 6 μl 1M HCl  15 min  6 μl 1M NaOH 
 Nucleus accumbens: 20 μl of sample + 175 μl of Hanks + 6 μl 1M HCl  15 min  6 μl 1M NaOH 
 Substantia nigra: 20 μl of sample + 175 μl of Hanks + 6 μl 1M HCl  15 min  6 μl 1M NaOH 
Ventral tegmental area: 30 μl of sample + 165 μl of Hanks + 6 μl 1M HCl  15 min  6 μl 1M NaOH 
- For NP++ lysed cell culture lysates (conc. ~1-3 μg/μl) 
 Primary CX/HC: 20 μl of sample + 175 μl of Hanks + 6 μl 1M HCl  15 min  6 μl 1M NaOH 
 MG87: 20 μl of sample + 175 μl of Hanks + 6 μl 1M HCl  15 min  6 μl 1M NaOH 
- Important note: Before running lots of samples, check (randomly 1 or 2 samples) the pH value using pH stick after HCl 
and NaOH (HCl pH ~3 NaOH  pH ~7)  
     Without acidic treatment 
 - (human)/rat serum/plasma (e.g. 1:25 in Hanks) 
III.Sample incubation 
- 170 μl/well of sample (in Hanks buffer) 
- 170 μl/well duplicates of BDNF- standards (Peprotech) in Hanks buffer (no acidic treatment) 
   Stock: 10 ng/μl aliquots (-80°C) 
   Make (1000), 500, 250, 125, 62.5, 31.2 pg/ml dilutions 
- 30 μl/well of POD-conjugated BDNF Ab#9_D antibody (-80°C; 1:1800 in Hanks buffer +6.66% BSA and  
    0.66% Triton X-100; e.g. 3 μl in 3.8ml) 
 Seal the plate and incubate overnight at +4ºC 
IV.Add substrate 
- Wash 4x with 300 μl PBS-T 
- Add 200 μl/well of BM blue POD substrate (100 ml bottle, store in dark at 4°C; Roche, take to RT 10-15 min use!). 
   - Incubate for 20 minutes at RT in a dark place 
   - Stop the reaction with 50 μl of 1 M H2SO4 (mix while pipetting) 
V. Count on Victor reader 
    - Measure in ELISA reader at 490 nm 
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REAGENTS 
Carbonate buffer 
 50 mM NaHCO3 (4.2 g/l, pH 8.2; RT, reagent room) + 50 mM Na2CO3, (5.3 g/1 l, pH 11.2; RT, reagent room), add 
until pH 9.7 (~210 ml) 
 Store in RT up to 3 months 
 
PBS-T 
 1/10 10x PBS in MilliQ water + 0.1% Tween 
 Store in RT up to 3 months 
 
Hanks buffer 
 Composition (for 1 l):  
125 mM NaCl (41.7 ml of 3 M stock solution), 5 mM KCl (5 ml of 1 M stock solution), 1.2 mM NaH2PO4 (1 ml of 1.2 
M stock solution), 1 mM CaCl2 (1 ml of 1 M stock solution), 1.2 mM MgCl2 (1.2 ml of 1 M stock solution), 1 μM ZnCl2 
(1 ml of 1 mM stock solution), 10 mM Glucose (1.9817 g), 25 mM HEPES (25 ml of 1 M stock solution), 0,25% BSA 
(2.5 g for 1 l), pH 7.4 (adjusted with NaOH) 
 Store at 4°C up to 3 months 
 
Blocking buffer (make 100-500 ml) 
 Hanks buffer, 2% BSA, 0.1% Triton X-100 
 Store at 4°C up to 3 months 
 
